Melanocortin receptor binding mimetibodies, compositions,...

Details Melanocortin receptor binding mimetibodies, compositions,... Melanocortin receptor binding mimetibodies, compositions,...

2011-03-22

2011-03-22

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C530S300000, C530S387100, C512S002000

Reexamination Certificate

active

07910101

ABSTRACT:
Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed.

REFERENCES:
patent: 4301045 (1981-11-01), Kaiser et al.
patent: 4415546 (1983-11-01), Ramachandran et al.
patent: 4457864 (1984-07-01), Hruby et al.
patent: 4485039 (1984-11-01), Hruby et al.
patent: 4649191 (1987-03-01), Hruby
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4866038 (1989-09-01), Hruby et al.
patent: 4918055 (1990-04-01), Hruby et al.
patent: 5028592 (1991-07-01), Lipton
patent: 5049547 (1991-09-01), Hruby et al.
patent: 5532347 (1996-07-01), Cone et al.
patent: 5622860 (1997-04-01), Yamada et al.
patent: 5674839 (1997-10-01), Hruby et al.
patent: 5683981 (1997-11-01), Hadley et al.
patent: 5703220 (1997-12-01), Yamada et al.
patent: 5714576 (1998-02-01), Hruby et al.
patent: 5731408 (1998-03-01), Hadley et al.
patent: 5824307 (1998-10-01), Johnson
patent: 5849871 (1998-12-01), Cone et al.
patent: 5869257 (1999-02-01), Yamada et al.
patent: 5877154 (1999-03-01), Naveh
patent: 5891847 (1999-04-01), Naveh
patent: 5908609 (1999-06-01), Lee et al.
patent: 6100048 (2000-08-01), Cone et al.
patent: 6117975 (2000-09-01), Yamada et al.
patent: 6127150 (2000-10-01), Coolidge et al.
patent: 6147195 (2000-11-01), Scherz et al.
patent: 6203995 (2001-03-01), Stark
patent: 6287763 (2001-09-01), Lee et al.
patent: 6323178 (2001-11-01), Hale et al.
patent: 6448032 (2002-09-01), Wikberg et al.
patent: 6573070 (2003-06-01), MacNeil et al.
patent: 6689938 (2004-02-01), Brennan et al.
patent: 6716810 (2004-04-01), Brennan et al.
patent: 6734175 (2004-05-01), Hadcock et al.
patent: 6797493 (2004-09-01), Sun et al.
patent: 6894028 (2005-05-01), Lipton et al.
patent: 7084111 (2006-08-01), Haskell-Luevano
patent: 7241733 (2007-07-01), Heavner et al.
patent: 7393662 (2008-07-01), Heavner et al.
patent: 2003/0171295 (2003-09-01), Lee et al.
patent: 2003/0229025 (2003-12-01), Xiao et al.
patent: 2005/0038230 (2005-02-01), Sharma et al.
patent: 2007/0135338 (2007-06-01), O'Neil et al.
patent: 2009/0136505 (2009-05-01), Bentz et al.
patent: 0 917 571 (2004-12-01), None
patent: WO 00/04873 (2000-02-01), None
patent: WO 00/33658 (2000-06-01), None
patent: WO 02/06316 (2002-01-01), None
patent: WO 03/073056 (2003-09-01), None
Aalberse et al., IgG4 breaking the rules, Immunol. 105:9-19, 105.
Sawyer, et al., “[half-Cys4, half-Cys10]-α-Melanocyte-stimulating hormone: A cyclic α-melanotropin exhibiting superagonist biological activity,” Proceeding of the National Academy of Science USA, 79: 1751-1755 (1982).
Dhillo, et al., “Hypothalamic peptides as drug targets for obesity,” Current Opinion in Pharmacology, 1: 651-655 (2001).
Mountjoy, et al., “Agouti Antagonism of Melanocortin-4 Receptor: Greater Effect with Desacetyl-α-Melanocyte-Stimulating Hormone (MSH) than with α-MSH,” Endocrinology, 140(5): 2167-2172 (1999).
Michaud, et al., “Obesity and the Adipocyte. Role of theagoutigene in obesity,” Journal of Endocrinology, 155: 207-209 (1997).
Ollmann, et al., “Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein,” Science, 278: 135-138 (1997).
Fehm, et al., “The Melanocortin Melanocyte-Stimulating Hormone/Adresnocorticotropin4-10Decreases Body Fat in Humans,” The Journal of Clinical Endocrinology & Metabolism, 86(3): 1144-1148 (2001).
Fan, et al., “Role of melanocortinergic neurons in feeding and theagoutiobesity syndrome,” Letters to Nature, 385: 165-168 (1997).
Lu, et al, “Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor,” Letters to Nature, 371: 799-802 (1994).
Farooqi, et al., “Clinical Spectrum of Obesity and Mutations in the Melanocortin 4 Receptor Gene,” The New England Journal of Medicine, 348(12): 1085-1095 (2003).
Froidevaux, et al., “A novel DOTA-alpha-melanocyte-stimulating hormone analog for metastatic melanoma diagnosis,” Journal of Nuclear Medicine, 43(12): 1699-1706 (2002).
Haskell-Luevano, et al., “Truncation studies of alpha-melanotropin peptides identify tripeptide analogues exhibiting prolonged agonist bioactivity,” Peptides, 17(6): 995-1002 (1996).
Supplemental EP Search Report dated Sep. 14, 2009 generated for Publication No. W02006/047535.

Affiliated with

Also associated with

Rating

Melanocortin receptor binding mimetibodies, compositions,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Melanocortin receptor binding mimetibodies, compositions,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Melanocortin receptor binding mimetibodies, compositions,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2728062